Your browser of choice has not been tested for use with Barchart.com. If you have issues, please download one of the browsers listed here.
Stocks | Futures | Watchlist | More
or

Roche Holdings Ltd ADR (RHHBY)

Roche Holdings Ltd ADR (RHHBY)

[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [OTC US]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (Cboe BZX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [OTC US]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
Quote Overview for [[ item.sessionDateDisplayLong ]]
[[ rowChartData.labelLow ]]
[[ rowChartData.lowPriceFormatted ]]
[[ rowChartData.lowPrice ]]
[[ rowChartData.labelHigh ]]
[[ rowChartData.highPriceFormatted ]]
[[ rowChartData.highPrice ]]
since [[ rowChartData.lowDate ]]
since [[ rowChartData.highDate ]]
[[ value ]] [[ value ]]

Fundamentals

See More
  • Market Capitalization, $K 282,089,216
  • Shares Outstanding, K 6,848,488
  • Annual Sales, $ 60,830 M
  • Annual Income, $ 10,735 M
  • 60-Month Beta 0.50
  • Price/Sales N/A
  • Price/Cash Flow 14.36
  • Price/Book 9.02
  • Price/Earnings ttm 0.00
  • Earnings Per Share ttm 0.00
  • Most Recent Earnings N/A on N/A
  • Next Earnings Date 01/30/20
  • Annual Dividend & Yield 0.68 (1.65%)
  • Most Recent Dividend 0.678 on 03/07/19
  • Sectors:

Analyst Rating / Earnings Estimates

Current Rating
See More
Strong Buy
Based on 6 analysts offering recommendations.
Earnings Estimates - Current Qtr 12/31/19
See More
  • Average Estimate 1.14
  • Number of Estimates 1
  • High Estimate 1.14
  • Low Estimate 1.14
  • Prior Year N/A
  • Growth Rate Est. (year over year) -99.89%

Price Performance

See More
Period Period Low Period High Performance
1-Month
40.3600 +3.28%
on 01/03/20
42.8800 -2.79%
on 01/22/20
+1.0450 (+2.57%)
since 12/27/19
3-Month
36.9700 +12.75%
on 11/05/19
42.8800 -2.79%
on 01/22/20
+4.7350 (+12.81%)
since 10/29/19
52-Week
31.8050 +31.06%
on 05/13/19
42.8800 -2.79%
on 01/22/20
+9.4150 (+29.18%)
since 01/29/19

Most Recent Stories

More News
Novartis (NVS) Earnings and Revenues Miss Estimates in Q4

Novartis (NVS) reports disappointing results for the fourth quarter but provides an encouraging outlook for 2020.

RHHBY : 41.6700 (+1.17%)
NVS : 96.54 (+1.05%)
BAYRY : 20.6850 (-1.08%)
REGN : 341.77 (-0.67%)
Can Biogen (BIIB) Keep the Earnings Streak Alive in Q4?

Biogen's (BIIB) fourth-quarter MS franchise sales are expected to have been flat. Spinraza U.S. sales are expected to have been supported by continued patient growth.

RHHBY : 41.6700 (+1.17%)
GILD : 64.32 (-0.06%)
ALXN : 108.33 (+1.27%)
BIIB : 281.05 (-0.32%)
Roche Submits Application for Tecentriq-Avastin Combo in HCC

Roche (RHHBY) submits sBLA for the label expansion of the Tecentriq-Avastin combo to treat HCC patients who have not received prior systemic therapy.

MRK : 87.76 (+1.75%)
BMY : 64.61 (-0.31%)
RHHBY : 41.6700 (+1.17%)
EXEL : 17.87 (-0.06%)
Roche's Urothelial Cancer Study on Tecentriq Disappoints

Roche's (RHHBY) study on Tecentriq in muscle-invasive urothelial cancer fails to meet goals.

MRK : 87.76 (+1.75%)
BMY : 64.61 (-0.31%)
AZN : 49.99 (+0.79%)
RHHBY : 41.6700 (+1.17%)
Epizyme Gets FDA Nod for Lead Drug in Epithelioid Sarcoma

Epizyme (EPZM) gets a significant boost with the approval of Tazverik (tazemetostat) for the treatment of metastatic or locally advanced epithelioid sarcoma.

RHHBY : 41.6700 (+1.17%)
GSK : 47.19 (+0.83%)
ALXN : 108.33 (+1.27%)
EPZM : 21.98 (+0.78%)
Pharma Stock Roundup: J&J's Mixed Q4, Roche & Novartis' New Drugs Approval in EU

J&J (JNJ) announces mixed Q4 results. Roche's (RHHBY) lymphoma drug, Polivy and Novartis' (NVS) Mayzent for secondary progressive multiple sclerosis (SPMS) get approval in Europe.

MRK : 87.76 (+1.75%)
PFE : 37.64 (-1.31%)
AZN : 49.99 (+0.79%)
RHHBY : 41.6700 (+1.17%)
GSK : 47.19 (+0.83%)
JNJ : 150.82 (+0.88%)
NVS : 96.54 (+1.05%)
J&J's Stelara Gets EU Nod for Plaque Psoriasis in Children

Johnson & Johnson (JNJ) receives the European Commission's (EC) nod to the line extension of Stelara to treat six to 11-year-old pediatric patients with moderate-to-severe plaque psoriasis.

JNJ : 150.82 (+0.88%)
LLY : 140.88 (+1.16%)
BMY : 64.61 (-0.31%)
RHHBY : 41.6700 (+1.17%)
How Does This Frothy Stock Market Run End?

How Does This Frothy Stock Market Run End?

RHHBY : 41.6700 (+1.17%)
MEI : 35.70 (-0.72%)
BDC : 49.91 (-0.16%)
BioLineRx Concludes Recruitment in Pancreatic Cancer Study

BioLineRx (BLRX) closes patient recruitment in the triple combination arm of the phase IIa COMBAT/KEYNOTE-202 study on Motixafortide to treat second-line metastatic pancreatic cancer.

MRK : 87.76 (+1.75%)
RHHBY : 41.6700 (+1.17%)
BLRX : 2.44 (-1.56%)
KALV : 16.29 (-1.03%)
Roche's Risdiplam Meets Primary Endpoint in Infants Study

Roche's (RHHBY) risdiplam meets primary endpoint in FIREFISH study in infants with type 1 spinal muscular atrophy.

RHHBY : 41.6700 (+1.17%)
NVS : 96.54 (+1.05%)
BIIB : 281.05 (-0.32%)
PTCT : 51.93 (+0.78%)

Barchart Technical Opinion

The Barchart Technical Opinion rating is a 96% Buy with a Strongest short term outlook on maintaining the current direction.

Long term indicators fully support a continuation of the trend.

See More Share

Trade RHHBY with:

Key Turning Points

2nd Resistance Point 41.4100
1st Resistance Point 41.3000
Last Price 41.6700
1st Support Level 41.1000
2nd Support Level 41.0100

See More

52-Week High 42.8800
Last Price 41.6700
Fibonacci 61.8% 38.6493
Fibonacci 50% 37.3425
Fibonacci 38.2% 36.0356
52-Week Low 31.8050

See More

Want to use this as
your default charts setting?
Learn about our Custom Templates
Switch the Market flag
above for targeted data.
Open the menu and switch the
Market flag for targeted data.
Get Streaming Chart Updates
Switch your Site Preferences
to Interactive Chart
Need More Chart Options?
Right-click on the chart to open the Interactive Chart menu.

Free Barchart Webinar